Open AccessEffect of angiotensin converting enzyme gene polymorphism on patients with in-stent restenosis after percutaneous coronary intervention
Author(s) -
Tarek A. Abdelaziz,
Randa H. Mohamed,
Gehan F. Balata,
Omar Y. El-Azzazy
Publication year - 2022
Publication title -
tropical journal of pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.209
H-Index - 36
eISSN - 1596-5996
pISSN - 1596-9827
DOI - 10.4314/tjpr.v20i2.26
Subject(s) - angiotensin converting enzyme , percutaneous coronary intervention , restenosis , medicine , genotype , gene polymorphism , conventional pci , single nucleotide polymorphism , coronary artery disease , bare metal stent , population , allele , stent , cardiology , pharmacology , gene , drug eluting stent , biology , genetics , myocardial infarction , environmental health , blood pressure
Purpose: To evaluate the association between common single nucleotide polymorphisms (SNPs) in angiotensin converting enzyme (ACE) gene and the risk of in-stent restenosis (ISR) and/or the response to angiotensin converting enzyme inhibitor ACEI in individuals with stable coronary artery disease (CAD) after stent implantation.
Methods: The total population of this study consisted of 200 Egyptian individuals divided into 2 groups - in-stent restenosis (ISR) and non ISR group). Genomic DNA was withdrawn from EDTA whole blood applying a spin column approach and ACE gene insertion/deletion (I/D) polymorphisms were determined by polymerase chain reaction (PCR).
Results: Carriers of allele D of ACE gene were significantly more liable to ISR occurrence. However, carriers of allele I were significantly more liable to ISR occurrence after administration of ACEI. There is a negative interaction between DD genotype of ACE gene and ACEI administration on ISR after percutaneous coronary intervention (PCI). However, there is a positive interaction between II and ID genotype of ACE gene and ACEI administration on ISR after PCI with bare metal stents (BMS).
Conclusion: It is beneficial to implement ACEI in therapeutic regimen in individuals with ID or II genotypes of ACE gene, especially with BMS implementation.